France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge Bio AG. The partnership focuses on discovering and developing biparatopic antibody (BPA) drug candidates against multiple targets, with therapeutic applications in precision oncology, dermatology, and rare diseases.
Collaboration Details
Under the agreement, RedRidge Bio will be responsible for engineering, screening, and characterizing BPAs against a jointly nominated portfolio of targets. Pierre Fabre will contribute its drug development expertise to drive two co-development programs through clinical development. Red Ridge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre will retain exclusive rights for the rest of the world. Additionally, Pierre Fabre will obtain exclusive worldwide rights for a third program after RedRidge hands it off at the preclinical stage.
Financial Arrangements
Financial details of the agreement were not disclosed. However, Pierre Fabre will support RedRidge’s Series A financing and make upfront, milestone, and future sales royalty payments. R&D costs for the co-development programs will be shared between the two parties.-Fineline Info & Tech
Leave a Reply